microRNA 1307 (miR-1307)

MicroRNA 1307 (miR-1307) is a small non-coding RNA that modulates gene expression by binding to complementary sequences within target messenger RNAs (mRNAs), leading to their degradation or inhibition of translation. miR-1307 exists in two major mature forms (miR-1307-3p and miR-1307-5p), both implicated in disease. It is overexpressed in multiple human cancers such as breast cancer and oral squamous cell carcinoma, where it promotes proliferation, migration, invasion, angiogenesis, and chemoresistance[1][2]. miR-1307-5p, specifically, is a promising non-invasive biomarker for oral cancer prognosis, while miR-1307-3p is associated with aggressive breast cancer features and contributes to the regulation of key genes like PRM2, EHF, RNF4, and others[1][2]. Additionally, miR-1307-3p has been linked to the host response to SARS-CoV-2 infection, modulating pathogenesis and potentially affecting disease severity[3]. Its central role in post-transcriptional gene regulation substantiates its status as both a biomarker and a potential therapeutic target, but therapeutic targeting must consider off-target risks and impacts on normal cellular processes[1][2][3].

Other names

MIR1307hsa-mir-1307mir-1307MIRN1307miRNA-1307-3pmiRNA-1307-5p

Post-transcriptional gene silencing via mRNA degradation or translation inhibition\nModulation of biological pathways such as cell cycle, NF-κB/MAPK signaling, and resistance to apoptosis[1][2][3]